JP2024501771A5 - - Google Patents
Info
- Publication number
- JP2024501771A5 JP2024501771A5 JP2023540927A JP2023540927A JP2024501771A5 JP 2024501771 A5 JP2024501771 A5 JP 2024501771A5 JP 2023540927 A JP2023540927 A JP 2023540927A JP 2023540927 A JP2023540927 A JP 2023540927A JP 2024501771 A5 JP2024501771 A5 JP 2024501771A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- substitution
- amino acid
- acid sequence
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134412P | 2021-01-06 | 2021-01-06 | |
| US63/134,412 | 2021-01-06 | ||
| PCT/US2022/011504 WO2022150521A1 (en) | 2021-01-06 | 2022-01-06 | Anti-pd-l1 antibodies and fusion proteins thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501771A JP2024501771A (ja) | 2024-01-15 |
| JP2024501771A5 true JP2024501771A5 (enExample) | 2025-01-09 |
Family
ID=82357548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540927A Pending JP2024501771A (ja) | 2021-01-06 | 2022-01-06 | 抗ｐｄ－ｌ１抗体及びその融合タンパク質 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240067729A1 (enExample) |
| EP (1) | EP4274614A4 (enExample) |
| JP (1) | JP2024501771A (enExample) |
| KR (1) | KR20230131236A (enExample) |
| CN (1) | CN116829188A (enExample) |
| AU (1) | AU2022206264A1 (enExample) |
| CA (1) | CA3173557A1 (enExample) |
| IL (1) | IL304190A (enExample) |
| MX (1) | MX2023008028A (enExample) |
| WO (1) | WO2022150521A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3173145A1 (en) * | 2020-07-03 | 2022-01-06 | Palleon Pharmaceuticals Inc. | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same |
| AU2022206263A1 (en) * | 2021-01-06 | 2023-07-20 | Palleon Pharmaceuticals Inc. | Sialidase-her2-antibody fusion proteins and methods of use thereof |
| CN120779021A (zh) * | 2024-04-08 | 2025-10-14 | 菲鹏生物股份有限公司 | 抗体缀合物及其用途 |
| WO2026037175A1 (zh) | 2024-08-16 | 2026-02-19 | 上海宝济药业股份有限公司 | 靶向靶细胞的复合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2368914T3 (en) * | 2006-03-10 | 2019-03-04 | Wyeth Llc | Anti-5T4 antibodies and uses thereof |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| KR20150131208A (ko) * | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2016160792A1 (en) * | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| WO2018231661A1 (en) * | 2017-06-12 | 2018-12-20 | Tianxin Wang | Methods and reagents to treat tumor and cancer |
| CN109970857B (zh) * | 2017-12-27 | 2022-09-30 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| EP3735458A4 (en) * | 2018-01-03 | 2022-04-27 | Palleon Pharmaceuticals Inc. | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF |
| EP3569618A1 (en) * | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| CN111606995B (zh) * | 2019-06-04 | 2021-02-12 | 优睿赛思(武汉)生物科技有限公司 | 抗人pd-l1单克隆抗体及其应用 |
| CN111763259B (zh) * | 2020-09-03 | 2020-12-15 | 北京百奥赛图基因生物技术有限公司 | 抗cd40抗体及其用途 |
-
2022
- 2022-01-06 CN CN202280014778.0A patent/CN116829188A/zh active Pending
- 2022-01-06 KR KR1020237026702A patent/KR20230131236A/ko active Pending
- 2022-01-06 MX MX2023008028A patent/MX2023008028A/es unknown
- 2022-01-06 AU AU2022206264A patent/AU2022206264A1/en not_active Abandoned
- 2022-01-06 US US18/260,364 patent/US20240067729A1/en active Pending
- 2022-01-06 JP JP2023540927A patent/JP2024501771A/ja active Pending
- 2022-01-06 WO PCT/US2022/011504 patent/WO2022150521A1/en not_active Ceased
- 2022-01-06 CA CA3173557A patent/CA3173557A1/en active Pending
- 2022-01-06 EP EP22737135.8A patent/EP4274614A4/en not_active Withdrawn
-
2023
- 2023-07-02 IL IL304190A patent/IL304190A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024501771A5 (enExample) | ||
| JP2020186248A5 (enExample) | ||
| KR102917630B1 (ko) | 인간 Tim-3에 대한 모노클로날 항체 | |
| WO2023186120A1 (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2021508449A5 (enExample) | ||
| JP2019506140A5 (enExample) | ||
| JP2019504617A5 (enExample) | ||
| CN109476741A (zh) | 与cd38和pd-l1结合的分子 | |
| JP2022538894A5 (enExample) | ||
| JP2023532021A5 (enExample) | ||
| TW202233694A (zh) | 雙特異性抗體 | |
| EP4392457A2 (en) | Bispecific tetravalent antibody targeting egfr and her3 | |
| CN114786720A (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| KR20250028265A (ko) | 항체 및 이의 용도 | |
| JP2024501767A5 (enExample) | ||
| CN113461820B (zh) | 抗cd3人源化抗体 | |
| JP2024542944A (ja) | 抗メソテリンナノボディおよびその使用 | |
| EP3538552B1 (en) | Fab molecules with a rodent hinge region and a non-rodent ch1 region | |
| JP2024542235A5 (enExample) | ||
| JP2024501770A5 (enExample) | ||
| JP2023550191A (ja) | Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法 | |
| JP2023508366A (ja) | 二重特異性ｆｃｙｒｉｉｉ×ｃｄ３０抗体構築体の製造方法 | |
| KR20250027598A (ko) | Klrb1 결합제 및 이의 사용 방법 | |
| JP2024522092A5 (enExample) | ||
| JP2024500945A5 (enExample) |